Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000682
UniProt IDP29373
Primary gene name(s)CRABP2
Synonym gene name(s)unknown
Protein nameCellular retinoic acid-binding protein 2
Protein functionTransports retinoic acid to the nucleus. Regulates the access of retinoic acid to the nuclear retinoic acid receptors.
Subcellular locationCytoplasm. Endoplasmic reticulum. Nucleus. Note=Upon ligand binding, a conformation change exposes a nuclear localization motif and the protein is transported into the nucleus.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P29373
Gene Ontology
(Biological Process)
Complete annatation
embryonic forelimb morphogenesis [GO:0035115];
epidermis development [GO:0008544];
positive regulation of collateral sprouting [GO:0048672];
regulation of retinoic acid receptor signaling pathway [GO:0048385];
regulation of transcription, DNA-templated [GO:0006355];
retinoic acid metabolic process [GO:0042573];
signal transduction [GO:0007165]
Gene Ontology
(Molecular Function)
Complete annatation
retinal binding [GO:0016918];
retinoic acid binding [GO:0001972];
retinoid binding [GO:0005501];
retinol binding [GO:0019841];
transporter activity [GO:0005215]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytosol [GO:0005829];
endoplasmic reticulum [GO:0005783];
extracellular exosome [GO:0070062];
nucleoplasm [GO:0005654]
Protein-protein interaction107773
Phylogenetic treeP29373
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3unknownunknownunknown
AZA vs. DISU1.173004622042340.01457920306983080.294870316543206
AZA vs. IL7unknownunknownunknown
AZA vs. SAHAunknownunknownunknown
DISU vs. CD30.8563935382098530.1124839156894210.20448414678031
DISU vs. IL7-1.160502528512340.01120783010232080.12590017793777
DISU vs. SAHA-1.083933406938260.03613094947012880.231682432974289
DMSO vs. AZAunknownunknownunknown
DMSO vs. CD3unknownunknownunknown
DMSO vs. DISU-1.061249215583520.01847202488244880.279491380500506
DMSO vs. IL7unknownunknownunknown
DMSO vs. SAHAunknownunknownunknown
HIV vs. Mock in Activation-0.5516443029734370.4318829547268280.999983755607037
HIV vs. Mock in Latencyunknownunknownunknown
IL7 vs. CD3unknownunknownunknown
SAHA vs. CD3unknownunknownunknown
SAHA vs. IL7unknownunknownunknown
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.756563 0.297589
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00523 Alitretinoin approved, investigational unknown unknown
DB08127 1,3,3-trimethyl-2-[(1E,3E)-3-methylpenta-1,3-dien-1-yl]cyclohexene experimental unknown unknown
DB08455 9-(4-HYDROXY-2,6-DIMETHYL-PHENYL)-3,7-DIMETHYL-NONA-4,6,8-TRIENOIC ACID experimental unknown unknown
DB08467 6-(2,3,4,5,6,7-HEXAHYDRO-2,4,4-TRIMETHYL-1-METYLENEINDEN-2-YL)-3-METHYLHEXA-2,4-DIENOIC ACID experimental unknown unknown
DB00755 Tretinoin approved, investigational, nutraceutical unknown substrate

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1BLR NMR - A=2-138.
1BM5 NMR - A=2-138.
1CBQ X-ray 2.2Å A=2-138.
1CBS X-ray 1.8Å A=2-138.
1XCA X-ray 2.3Å A/B=2-138.
2CBS X-ray 2.1Å A=2-138.
2FR3 X-ray 1.4Å A=2-138.
2FRS X-ray 1.5Å A/B=2-138.
2FS6 X-ray 1.3Å A/B=2-138.
2FS7 X-ray 1.5Å A/B=2-138.
2G78 X-ray 1.7Å A=2-138.
2G79 X-ray 1.6Å A=2-138.
2G7B X-ray 1.1Å A=2-138.
3CBS X-ray 2.0Å A=2-138.
3CR6 X-ray 1.2Å A=2-138.
3CWK X-ray 1.6Å A=2-138.
3D95 X-ray 1.2Å A/B=2-138.
3D96 X-ray 1.7Å A/B=2-138.
3D97 X-ray 1.5Å A/B=2-138.
3F8A X-ray 1.9Å A=2-138.
3F9D X-ray 2.0Å A/B=2-138.
3FA6 X-ray 1.5Å A/B=2-138.
3FA7 X-ray 1.9Å A/B=2-138.
3FA8 X-ray 1.7Å A/B=2-138.
3FA9 X-ray 1.9Å A/B=2-138.
3FEK X-ray 1.5Å A/B=2-138.
3FEL X-ray 1.8Å A/B=2-138.
3FEN X-ray 1.5Å A/B=2-138.
3FEP X-ray 2.6Å A=2-138.
3I17 X-ray 1.6Å A/B=2-138.
4I9R X-ray 2.6Å A=2-138.
4I9S X-ray 2.5Å A=2-138.
4M6S X-ray 2.4Å A=2-138.
4M7M X-ray 2.5Å A=2-138.
4QGV X-ray 1.7Å A/B=2-138.
4QGW X-ray 1.7Å A/B=2-138.
4QGX X-ray 1.4Å A/B=2-138.
4YBP X-ray 1.8Å A=2-138.
4YBU X-ray 1.9Å A=2-138.
4YCE X-ray 1.9Å A=2-138.
4YCH X-ray 1.9Å A=2-138.
4YDA X-ray 1.9Å A=2-138.
4YDB X-ray 2.0Å A=2-138.
4YFP X-ray 1.9Å A=2-138.
4YFQ X-ray 1.6Å A=2-138.
4YFR X-ray 1.9Å A=2-138.
4YGG X-ray 1.9Å A=2-138.
4YGH X-ray 2.1Å A=2-138.
4YGZ X-ray 2.0Å A=2-138.
4YH0 X-ray 2.1Å A=2-138.
4YKM X-ray 1.5Å A/B=2-138.
4YKO X-ray 1.5Å A/B=2-138.
5HZQ X-ray 1.7Å A/B=1-138.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
not found